A recent study presented at the European Cancer Congress 2017 (ECCO 2017) in Amsterdam, the Netherlands, shows promise with a breath test measuring five chemicals in the detection of possible gastric and oesophageal cancers.
Results from a study presented at the European Cancer Congress 2017 (ECCO 2017) in Amsterdam, the Netherlands showed that rapid deterioration of type 2 diabetes after diagnosis may be an early sign of pancreatic cancer.
Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer.
Women above 50 years of age with ductal carcinoma in situ (DCIS) have a lower risk of all-cause mortality at 10 years compared with the general population, new data presented at the European Cancer Congress 2017 (ECCO 2017)have shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
New drug applications approved by US FDA as of 16 - 30 November 2018
which includes New Molecular Entities (NMEs) and new biologics. It does
not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]